论文部分内容阅读
目的 :在阿莫西林中加入不同比例的他唑巴坦后 ,观察其对临床分离的128株致病菌的体外抗菌活性 ,并与阿莫西林/舒巴坦、阿莫西林/克拉维酸比较抗菌活性的强弱。方法 :用2倍稀释法检测4种抗菌药物对临床分离的128株致病菌的体外抗菌活性。结果 :阿莫西林/他唑巴坦 (2∶1)的MIC50 值分别是阿莫西林/他唑巴坦 (4∶1)与 (8∶1)的1/4～1/8 ,是阿莫西林/克拉维酸(2∶1)及阿莫西林/舒巴坦 (2∶1)的1/2～1/4 ;其MIC90 值分别是阿莫西林/他唑巴坦 (4∶1)与 (8∶1)的相同值或1/4 ,是阿莫西林/克拉维酸 (2∶1)与阿莫西林/舒巴坦 (2∶1)的1/2～1/4。结论 :与其它联合制剂相比 ,阿莫西林/他唑巴坦抗菌作用最强 ,并且其2∶1的比例体外抗菌效果最好。
OBJECTIVE: To observe the in vitro antibacterial activity of amoxicillin against 128 pathogenic bacteria isolated from amoxicillin after adding different ratios of tazobactam to amoxicillin / sulbactam, amoxicillin / clavulanate Compare the strength of antibacterial activity. Methods: In vitro antibacterial activity of four antibacterial agents against 128 pathogenic bacteria isolated clinically was tested by 2-fold dilution method. Results: The MIC50 values of amoxicillin / tazobactam (2: 1) were 1 / 4-1 / 8 of amoxicillin / tazobactam (4: 1) and The MIC90 values were 1 to 4 for moxillin / clavulanic acid (2: 1) and 1 for amoxicillin / sulbactam (2: 1) ) Is the same value or ¼ as that of (8: 1) and is ½ to ¼ of that of amoxicillin / clavulanic acid (2: 1) and amoxicillin / sulbactam (2: 1). CONCLUSION: Amoxicillin / tazobactam has the strongest antimicrobial activity compared with other combinations, and its 2: 1 ratio has the best antibacterial activity in vitro.